John Blankenhorn

InvestorPlace Contributor

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

The 3 Most Promising Energy Storage Stocks for April 2023

By John Blankenhorn, InvestorPlace Contributor May 1, 2023

Here are three energy storage stocks from companies who are delivering the scale needed to help renewable energy efforts possible.

The 3 Most Promising Gene Editing Stocks to Buy in 2023

By John Blankenhorn, InvestorPlace Contributor Apr 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

3 Cash-Rich Biotech Stocks to Bet on for the Long Haul

By John Blankenhorn, InvestorPlace Contributor Apr 25, 2023

Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch.

3 Biotech Stocks to Sell Before They’re 6 Feet Under

By John Blankenhorn, InvestorPlace Contributor Apr 24, 2023

Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid.

3 Stocks to Buy That Could Be the Next Gaming Phenomenon

By John Blankenhorn, InvestorPlace Contributor Apr 17, 2023

Gaming is fun, and gaming stocks can be profitable. Here's three stocks with the tech and the art to be gaming phenomena.